“…Due to our patient’s marked drop in platelets, intermediate 4T score, and positive PF4 IgG antibodies, there was clinical suspicion for type II HIT and the decision was made to switch from unfractionated heparin to argatroban. Argatroban and bivalirudin are approved intravenous anticoagulants in suspected and confirmed HIT [ 3 , 4 ]. Alternatives to these therapies, including fondaparinux and direct oral anticoagulants, have also been studied and shown to have similar rates of platelet recovery, safety profiles (i.e., major bleeding), and risk of new or worsening thromboembolism [ 4 , 9 ].…”